Lung adenocarcinoma
Conditions
Interventions
Case series:pemetrexed combined with EGFR-TKIs
Sponsors
Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The histologic diagnosis of Non-squamous NSCLC patients staged IV; 2. EGFR sensitive mutation positive; 3. ECOG score 0-1; 4. Male or female aged 18-75 years; 5. Expected survival is more than 3 months; 6. At least one evaluable lesion; 7. Plan to receive pemetrexed plus platinum plus EGFR-TKIs.
Exclusion criteria
Exclusion criteria: 1. Previous use of pemetrexed or EGFR TKIs 2. If you ever have received adjuvant or neoadjuvant chemotherapy, at the end of the treatment to the recurrence time 6 months 3. Confirmed allergy to pemetrexed or egfr-tkis and/or its excipients 4. Women who are pregnant, or who are currently trying to have a pregnancy, or who have the possibility of having a child and are not using contraception 5. Patients with contraindications to pemetrexed or egfr-tkis 6. Having meningeal metastasis or symptomatic central nervous system metastasis 7. Accompanied by other malignant tumors (except those with radical treatment, such as cervical carcinoma in situ, non-melanoma skin cancer, etc.) 8.Those not considered suitable for inclusion by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective remission rate;Disease control rate; | — |
Countries
China
Contacts
Public ContactHuijuan Wang
Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University
Outcome results
None listed